ZC3H15 in pancreatic cancer growth and treatment response
Official title: Role of ZC3H15 in Pancreatic Cancer Pathogenesis and Therapeutic Response
Funded at University of Oklahoma Hlth Sciences Ctr · NIH-11433670 · Data updated 2026-11-12
A study exploring how the protein ZC3H15 affects the progression of pancreatic cancer and how it responds to therapies, with the goal of helping patients with this very deadly cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | June 15, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $407,726 |
| NIH project number | 1R01CA316828-01 |
| Project ID | NIH-11433670 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients whose cancer is pancreatic ductal adenocarcinoma (PDAC) and whose tumors express ZC3H15 or are likely to have therapy-resistant disease.
✕Less likely to help
If pancreatic tumors do not involve ZC3H15 or do not respond to the proposed strategies, patients may not benefit.
What this research studies
This project looks at why pancreatic cancer is so hard to treat by focusing on ZC3H15, a protein found more in therapy‑resistant tumors. Researchers will use a combination of lab methods, including analyzing RNA and metabolites and testing effects in model systems, to understand how ZC3H15 drives tumor growth and treatment response. The work aims to identify new ways to slow cancer or improve how existing therapies work for patients with PDAC. The study builds on prior findings that link high ZC3H15 levels to worse survival and therapy resistance. If successful, the research could point to new treatment strategies for pancreatic cancer patients who currently have limited options.
Why it matters
Potential benefit: It could lead to new targets or combinations that improve survival and response to therapy for pancreatic cancer patients.
How similar studies have gone: Prior work suggests ZC3H15 is linked to tumor growth and therapy resistance, supporting the potential of this approach but with ongoing need for validation.
Where this research is happening
-
University of Oklahoma Hlth Sciences Ctr
Oklahoma City, United States Active
Researchers
- Principal investigator: Shukla, Surendra K — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Shukla, Surendra K
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.